ABSTRACT
As a clinical test, direct observation of the middle ear should be ideally performed without any surgical intervention such as myringotomy. This paper reports a newly invented superfine fiberscope which makes it possible to insert through the eustachian tube, and direct views of the middle ear structures on normal subjects and patients. The patients were of a small cholesteatoma and traumatic dislocation of the ossicular chain. All of them were tested with local anesthesia in outpatient clinic. This superfine fiberscope was of great value in observing of middle ear structures as a diagnostic instruments, as that no surgical intervention was necessary in the procedure.
Subject(s)
Ear, Middle/pathology , Adult , Cholesteatoma/diagnosis , Ear Diseases/diagnosis , Ear Ossicles/injuries , Ear, Middle/anatomy & histology , Endoscopes , Equipment Design , Female , Fiber Optic Technology/instrumentation , Humans , Joint Dislocations/diagnosis , Male , Middle Aged , Predictive Value of TestsABSTRACT
A clinical trial of moderate dose methotrexate (MTX)-CF rescue was conducted in 12 institutions. Thirty-seven patients with head and neck carcinoma entered this trial, of which 32 were evaluable. MTX was administered 350 mg/m2 (500 mg/body) by i.v. drip over 6 hours. Three hours after completion of MTX infusion, CF rescue was started. There was no complete response in 32 patients. Nine patients showed partial response with the response rate of 28%. The response rates were 21% for the group of patients treated previously, and 75% for the group untreated previously. MTX concentration in plasma was determined at 6, 24, 48 and 72 hours after the initiation of MTX infusion, and the assay results revealed a safe range. GI disturbances were seen at the rates of 11 to 38%. Bone marrow suppression was mild and no renal toxicity was observed. We concluded that the moderate dose MTX-CF rescue therapy was useful for head and neck carcinoma. As a next step, we are planning to conduct a clinical trial of high-dose MTX.
